Needham analyst Mike Matson initiates coverage on Penumbra (NYSE:PEN) with a Hold rating.
Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed the approval of Amryt Pharma Plc’s (NASDAQ:AMYT) Filsuvez…
